|1.||Tropical Spastic Paraparesis (Tropical Spastic Paraplegia)
|1.||Otto, Jürgen: 1 article (10/2010)|
|2.||Guan, Huai-jin: 1 article (10/2010)|
|3.||Kobylarz, Joanna: 1 article (01/2010)|
|4.||Pawińska-Wasikowska, Katarzyna: 1 article (01/2010)|
|5.||Balwierz, Walentyna: 1 article (01/2010)|
|6.||Romanowska-Dixon, Bozena: 1 article (01/2010)|
|7.||Pietrys, Danuta: 1 article (01/2010)|
|8.||Moryl-Bujakowska, Angelina: 1 article (01/2010)|
|9.||Marshall, Ernest: 1 article (06/2006)|
|10.||O'Neill, Penny A: 1 article (06/2006)|
01/01/1994 - "The uveal disease was characterized by acute, granulomatous or nongranulomatous anterior uveal involvement and granular or membranous vitreous opacities with or without retinal vascular change. "
12/01/1956 - "Retinal lesions associated with uveal disease. "
08/01/1970 - "[Dynamics of plasma kinin in eye diseases and effects of anti-kinin agents with special reference to retinal and uveal diseases]."
10/01/2010 - "For example, the secondary sampling epidemiologic study of disabled persons in China in 2006 showed that the major causes of blindness and vision impairment were cataract (56.7%), retinal and uveal diseases (14.1%) and corneal diseases (10.3%). "
02/01/1998 - "Latanoprost should be used with caution in pseudophakic and aphakic patients--especially those with retinal vascular fragility, any inflammatory uveal disease, or other factors that may predispose to the breakdown of the blood-retinal barrier."
|2.||Adrenal Cortex Hormones (Corticosteroids)IBA
01/01/1994 - "1) middle-aged adult of either sex develops acute, inflammatory uveal disease and presents with visual haze or floaters, or both; 2) active disease consists of granulomatous or nongranulomatous reactions accompanied by vitreous opacities and retinal vasculitis with rare retinochoroidal exudative changes; 3) the disease resolves with response to corticosteroids, although leaving sequelae in occasional cases; 4) the disease affects one or both eyes, and up to half of cases show recurrent disease within years; 5) the visual outcome is usually favorable; 6) the disease occurs as an isolated disorder, but may sometimes be complicated by HTLV-I associated myelopathy. "
09/01/1994 - "Assuming that a collection of 50 cases of HTLV-I seropositive, etiology-undefined uveitis represents HAU, its clinical features consisted were: (1) middle-aged, otherwise healthy adults developed acute inflammatory uveal disease and presented with visual haze and/or floaters; (2) the disease showed granulomatous or nongranulomatous anterior uveal reactions accompanied by vitreous opacities and retinal vasculitis; (3) the lesions resolved in response to topical or systemic corticosteroids; (4) the visual outcome was usually favorable; (5) nearly half of the cases had recurrent disease; (6) the cases remained systemically unremarkable, except for two cases of HTLV-I associated myelopathy and eight cases of hyper thyroid disease."
01/01/1997 - "Cytokines: their role in uveal disease."
|5.||Methotrexate (Mexate)FDA LinkGeneric
02/01/1966 - "Methotrexate treatment of uveal disease."
|6.||Diphtheria AntitoxinFDA Link
01/01/1994 - "All of the patients had serum antibodies to HTLV-I. The uveal disease resembled HTLV-I associated uveitis that may develop in patients with HTLV-I associated myelopathy or HTLV-I carriers; 2 cases had chronic myelopathy or arthropathy that was considered associated with the retrovirus. "
|9.||Acyclovir (Aciclovir)FDA LinkGeneric
|10.||latanoprost (Xalatan)FDA Link
|1.||Drug Therapy (Chemotherapy)